XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - Unaudited - USD ($)
$ in Thousands
Total
Redeemable Noncontrolling Interest
Class A Common Stock
Class B Common Stock
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Class A Common Stock
Accumulated Deficit
Total vTv Therapeutics Inc Stockholders’ Equity (Deficit)
Noncontrolling Interest
Beginning balance at Dec. 31, 2022   $ 16,579                  
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Change in redemption value of noncontrolling interest $ (1,104) (1,104)                  
Net loss attributable to vTv Therapeutics Inc.   (4,753)                  
Ending balance at Sep. 30, 2023   10,722                  
Beginning balance, shares (in shares) at Dec. 31, 2022         2,084,973 577,349          
Beginning balance at Dec. 31, 2022 (10,740)       $ 21 $ 6 $ 254,757   $ (265,524)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss attributable to vTv Therapeutics Inc. (16,772)               (16,772)    
Change in redemption value of noncontrolling interest 1,104               1,104    
Share-based compensation 1,175           1,175        
Ending balance, shares (in shares) at Sep. 30, 2023 [1]         2,084,973 577,349          
Ending balance at Sep. 30, 2023 (25,233)       $ 21 [1] $ 6 [1] 255,932 [1]   (281,192)    
Beginning balance at Jun. 30, 2023   18,879                  
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Change in redemption value of noncontrolling interest   (6,271)                  
Net loss attributable to vTv Therapeutics Inc.   (1,886)                  
Ending balance at Sep. 30, 2023   10,722                  
Beginning balance, shares (in shares) at Jun. 30, 2023 [1]         2,084,973 577,349          
Beginning balance at Jun. 30, 2023 (25,283)       $ 21 [1] $ 6 [1] 255,499 [1]   (280,809)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss attributable to vTv Therapeutics Inc. (6,654)               (6,654)    
Change in redemption value of noncontrolling interest 6,271               6,271    
Share-based compensation 433           433 [1]        
Ending balance, shares (in shares) at Sep. 30, 2023 [1]         2,084,973 577,349          
Ending balance at Sep. 30, 2023 (25,233)       $ 21 [1] $ 6 [1] 255,932 [1]   (281,192)    
Beginning balance at Dec. 31, 2023 6,131 6,131                  
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss attributable to redeemable noncontrolling interest [2]   (1,085)                  
Change in redemption value of noncontrolling interest (214) 214                  
Reclassification of redeemable noncontrolling interest to permanent equity 5,260 (5,260)                 $ 5,260
Ending balance at Sep. 30, 2024 0 0                  
Beginning balance, shares (in shares) at Dec. 31, 2023     2,084,973 577,349 2,084,973 577,349          
Beginning balance at Dec. 31, 2023 (24,680)       $ 21 $ 6 256,335   (281,042) $ (24,680) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss attributable to vTv Therapeutics Inc. (14,828)               (14,828) (14,828)  
Change in redemption value of noncontrolling interest (214)               (214) (214)  
Reclassification of redeemable noncontrolling interest to permanent equity 5,260 (5,260)                 5,260
Share-based compensation 1,932           1,932     1,932  
Issuance of Class A common stock and prefunded warrants, net offering costs (in shares)         347,884            
Issuance of Class A common stock and pre-funded warrants, net offering costs 50,335       $ 3     $ 50,332   50,335  
Issuance of Class A Common Stock under ATM offering (in shares)         179,400            
Issuance of Class A Common Stock under ATM offering 2,463       $ 2   2,461     2,463  
Net loss attributable to noncontrolling interest (2,355)                   (2,355)
Ending balance, shares (in shares) at Sep. 30, 2024     2,612,257 577,349 2,612,257 577,349          
Ending balance at Sep. 30, 2024 17,913       $ 26 $ 6 311,060   (296,084) 15,008 2,905
Ending balance at Sep. 30, 2024 0 $ 0                  
Beginning balance, shares (in shares) at Jun. 30, 2024         2,432,857 577,349          
Beginning balance at Jun. 30, 2024 20,437       $ 24 $ 6 307,746   (291,301) 16,475 3,962
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss attributable to vTv Therapeutics Inc. (4,783)               (4,783) (4,783)  
Share-based compensation 853           853     853  
Issuance of Class A Common Stock under ATM offering (in shares)         179,400            
Issuance of Class A Common Stock under ATM offering 2,463       $ 2   2,461     2,463  
Net loss attributable to noncontrolling interest (1,057)                   (1,057)
Ending balance, shares (in shares) at Sep. 30, 2024     2,612,257 577,349 2,612,257 577,349          
Ending balance at Sep. 30, 2024 $ 17,913       $ 26 $ 6 $ 311,060   $ (296,084) $ 15,008 $ 2,905
[1]
(*) Adjusted retroactively for reverse stock split
[2]
(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 7)